Resolutions at the Extraordinary General Meeting in Biotage AB on November 21, 2008

Resolutions at the Extraordinary General Meeting in Biotage AB on November 21,
2008

At the Extraordinary General Meeting held in Biotage AB (Reg. No. 556539-3138)
on November 21, 2008, the following resolution was passed.

Resolution on reduction of statutory reserve 
The General Meeting resolved to reduce the company's statutory reserve with an
amount of SEK 842.180.000 by means of transfer of the aforesaid amount to a
reserve to be used in accordance with resolution/s adopted at forthcoming
General Meetings. 

The statutory reserve will be entirely dissolved following the execution of the
said reduction. Approval by the Swedish Companies Registration Office (Sw.
Bolagsverket), or the general court (Sw. allmän domstol) in case of a dispute,
is required to effectuate the proposed reduction of statutory reserve. 

Uppsala, November 21, 2008
Biotage AB (publ)
The Board of Directors

Contact: 
Torben Jörgensen, President and CEO 
Tel: +46 707 49 05 84, torben.jorgensen@eu.biotage.com 

About Biotage 
Biotage is a global company active in life science research with strong
technologies, a broad range of operations and a long-term view of the market.
The company offers solutions, knowledge and experience in the area of medicinal
chemistry. In 2005 business and products from the company Argonaut were
acquired, further strengthening the product range in medicinal chemistry. The
customers include the worlds top 30 pharma companies, the worlds top 20 biotech
companies, and leading academic institutes. The company is headquartered in
Uppsala and has subsidiaries in the U.S., Japan, UK, Germany and several other
European countries. Biotage has 300 employees and had sales of SEK 496m in 2007.
Biotage is listed on the OMX Nordic stock exchange. Website: www.biotage.com